You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Medtronic
Johnson and Johnson
Harvard Business School

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CHLOROTHIAZIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Chlorothiazide patents expire, and what generic alternatives are available?

Chlorothiazide is a drug marketed by Abc Holding, Hikma Intl Pharms, Lederle, Mylan, Sandoz, Watson Labs, Hikma Pharms, Am Regent, Fresenius Kabi Usa, Mylan Institutional, Sagent Pharms Inc, and Sun Pharm. and is included in twenty-three NDAs.

The generic ingredient in CHLOROTHIAZIDE is chlorothiazide sodium. There are forty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the chlorothiazide sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Chlorothiazide

A generic version of CHLOROTHIAZIDE was approved as chlorothiazide sodium by FRESENIUS KABI USA on October 16th, 2009.

  Start Trial

Drug patent expirations by year for CHLOROTHIAZIDE
Drug Prices for CHLOROTHIAZIDE

See drug prices for CHLOROTHIAZIDE

Recent Clinical Trials for CHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of VirginiaPhase 4
Vanderbilt UniversityPhase 4
Yale UniversityN/A

See all CHLOROTHIAZIDE clinical trials

Pharmacology for CHLOROTHIAZIDE
Drug ClassThiazide Diuretic
Physiological EffectIncreased Diuresis
Medical Subject Heading (MeSH) Categories for CHLOROTHIAZIDE

US Patents and Regulatory Information for CHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abc Holding CHLOROTHIAZIDE chlorothiazide TABLET;ORAL 085569-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Institutional CHLOROTHIAZIDE SODIUM chlorothiazide sodium INJECTABLE;INJECTION 202493-001 Jun 18, 2014 AP RX No No   Start Trial   Start Trial   Start Trial
Mylan CHLOROTHIAZIDE-RESERPINE chlorothiazide; reserpine TABLET;ORAL 087745-001 May 6, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan CHLOROTHIAZIDE chlorothiazide TABLET;ORAL 084217-001 Approved Prior to Jan 1, 1982 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.